Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial

Naomi Balzer Haas, Judith B. Manola, Robert G. Uzzo et al. · The Lancet · 2016

Cited by 630 works. doi:10.1016/s0140-6736(16)00559-6

Authors

References